Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
Completed
Bioprojet
Phase 2
2007-10-01
The objective of this trial is to define the minimum effective dose of BF 2.649 between 5 mg,
10 mg, 20 mg or 40 mg versus placebo in reducing the Excessive Daytime Sleepiness of
Parkinson's disease patients
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Completed
Bioprojet
Phase 3
2009-12-01
To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the
long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649
in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinson's
Disease.
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Completed
Bioprojet
Phase 3
2010-03-01
To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the
long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649
in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinson's
Disease.
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy
Completed
Bioprojet
Phase 3
2009-05-01
The objective of this study is to evaluate the efficacy and safety of BF2.649 administered by
individual titration in narcoleptic patients with excessive daytime sleepiness (EDS)
Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy
Completed
Bioprojet
Phase 3
2009-10-01
The objective of this study is to evaluate and compare the efficacy and safety of escalating
doses of BF2.649 and BF2.649 add on Modafinil on cataplexy in patients with narcolepsy
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
